Data Visualization

Out-of-Pocket Costs for Specialty Drugs in Medicare Part D

Out-of-Pocket Costs for Specialty Drugs in Medicare

Recent Work

View All
  • Other Countries Control Drug Prices. The U.S. Could, Too.

    Public opinion surveys show that most Americans are deeply concerned about rising drug prices. That’s not surprising: Overall, we spend twice as much on drugs as our counterparts in other developed countries. For example, in 2015, the most recent year for which data are available, an American patient and insurer could expect to pay about $2,670 for a month’s supply of adalimumab, a... Read More

  • Policy Proposal: Allow Medicare to Negotiate Drug Prices in Part D

    Under the Part D program, private prescription drug plans provide drug coverage to Medicare enrollees. These plans negotiate drug rebates and other discounts with pharmaceutical manufacturers, which reduce program costs and allow plans to compete for beneficiaries based on lowering premiums and patient out-of-pocket costs. However, the federal government is prohibited from negotiating drug prices... Read More

  • Pew Offers Feedback on Potential Prescription Drug Models

    On Nov. 20, The Pew Charitable Trusts’ drug spending research initiative submitted comments to the Centers for Medicare & Medicaid Services in response to a request for information on a new direction for the Innovation Center. The comments discussed two areas where the Innovation Center could test prescription drug models with potential to increase competition, reduce costs to Medicare... Read More

Media Contact

Erin Davis

Officer, Communications